Cellular therapies in acute lymphoblastic leukemia

Por Brentjens, Renier J
Publicado no Curr Opin Mol Ther (2009)

Are Chimeric Antigen Receptor T Cells Ready for Prime Time?

Por Brentjens, Renier J.
Publicado no Clin Adv Hematol Oncol (2016)

CAR Therapy for CLL: What are the Challenges?

Por Davila, Marco L, Brentjens, Renier
Publicado em 2013

Medical management of side effects related to CAR T cell therapy in hematologic malignancies

Por Namuduri, Manjusha, Brentjens, Renier J
Publicado no Expert Rev Hematol (2016)

The basic principles of chimeric antigen receptor (CAR) design

Por Sadelain, Michel, Brentjens, Renier, Riviere, Isabelle
Publicado em 2013

Adoptive Immunotherapy for B-cell Malignancies with Autologous Chimeric Antigen Receptor Modified Tumor Targeted T Cells

Por Park, Jae H, Brentjens, Renier J
Publicado no Discov Med (2010)

Retroviral Transduction of Murine Primary T Lymphocytes

Por Lee, James, Sadelain, Michel, Brentjens, Renier
Publicado no Methods Mol Biol (2009)

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

Por Geyer, Mark B., Brentjens, Renier J.
Publicado no Cytotherapy (2016)

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

Por Yeku, Oladapo O., Brentjens, Renier J.
Publicado no Biochem Soc Trans (2016)

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen

Por Brentjens, Renier J., Curran, Kevin J.
Publicado no Hematology Am Soc Hematol Educ Program (2012)

CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Por Davila, Marco L., Brentjens, Renier J.
Publicado no Clin Adv Hematol Oncol (2016)

Overcoming Antigen Escape with CART-cell Therapy

Por Jackson, Hollie J., Brentjens, Renier J.
Publicado no Cancer Discov (2015)

Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies

Por Daniyan, Anthony F., Brentjens, Renier J.
Publicado no Nat Rev Clin Oncol (2017)

The promise and potential pitfalls of chimeric antigen receptors

Por Sadelain, Michel, Brentjens, Renier, Rivière, Isabelle
Publicado no Curr Opin Immunol (2009)

Development of CAR T cells designed to improve antitumor efficacy and safety

Por Jaspers, Janneke E., Brentjens, Renier J.
Publicado no Pharmacol Ther (2017)

Cellular Therapies in Acute Lymphoblastic Leukemia

Por Park, Jae H., Sauter, Craig, Brentjens, Renier
Publicado em 2011

CD19-targeted T Cells for Hematologic Malignancies: Clinical Experience to Date

Por Davila, Marco L, Sauter, Craig, Brentjens, Renier
Publicado no Cancer J (2015)

Adoptive T-Cell Therapy for Solid Tumors

Por Yeku, Oladapo, Li, Xinghuo, Brentjens, Renier J.
Publicado no Am Soc Clin Oncol Educ Book (2017)

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies

Por Daniyan, Anthony F. O., Brentjens, Renier J.
Publicado no J Leukoc Biol (2016)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Por Rafiq, Sarwish, Hackett, Christopher S., Brentjens, Renier J.
Publicado no Nat Rev Clin Oncol (2019)